Biomednewsbreaks Astiva Health Notes 'Outstanding Expansion' In 2024, Projects 'Substantial' Growth For 2025

(MENAFN- Investor Brand Network) Astiva Health , a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, is forecasting membership growth for 2025. This year the company has seen“outstanding expansion,” and based on that growth, Astiva Health anticipates have an additional 7,000 members join its unique, personalized plan membership in the upcoming year. According to the announcement, those numbers would represent a substantial 70% increase over its current membership base.

“We are thrilled to continue building on the momentum we've achieved this year,” said Astiva Health cofounder and CEO Dr. Tri T. Nguyen in the press release.“Our growth is a testament to the value our culturally aware, personalized healthcare model brings to our members. As we project adding another 7,000 members in 2025, we are committed to expanding our services and enhancing the quality of care we provide.”

To view the full press release, visit

About Astiva Health

Astiva Health is a fast-growing MAPD health plan committed to redefining personalized and comprehensive healthcare standards. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique needs of its members. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Astiva Health's dedication to serving the underserved population fulfills a critical societal need and also positions the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves. For more information about the company, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to Astiva are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN11092024000224011066ID1108663219